Overwight and Fat a Natural Treatment

Caigua (Cyclantera Pedata)
The amazing way to reduce cholesterol using
a 100% natural product.

CAIGUA RESEARCH
Documents related to the Andean Caigua scientic studies of health applications.

1.- Thompson, G.R. (1989) Current management of hyperlipidaemia. British Journal of Hospital Medicine, 42, 268-274.

2.- Thompson, G.R. (1993) Treatament of hyperlipidaemia. Clinical Endocrinology. 38: 337-342.

3.- La Rosa JC. (1993) Cholesterol lowering, low cholesterol, and mortality. Am. J. Cardio. 72: 776-786.

4.- Holme l. (1993) Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br. Heart J. 69 (suppl) S42-S47.

5.- Davies MJ., Krikler DM., Katz D. (1991) Atheroesclerosis: inhibition or regression as therapeutic possibilities. Br. Heart J. 65: 302-310.

6.- Pekkanem J., Linn S., Heiss G., Suchidran CM., Leon A., Rifkin BM., Tyroler HA. (1990) Ten year mortality from cardiovascular disease in relatio to cholesterol level among men with and wthout preexisting cardiovascular disease. N. Engel, J. Med. 322: 1700-1707.

7.- Wong ND., Wilson PWF., Kannel WB. (1991) Serum cholesterol as a prognostic factor after myocardial infarctio: The Framingham Study. Ann Intern Med 1991; 115: 687-693

8.- Solymoss BC., Marcil M., Wesolowska E., Gilfix BM., Lesperance J., Campeau L. (1993) Relation of coronary artery disease in women < 60 years of age to the combined elevation of serum lipoprotein /a) and total cholesterol to hight-density cholesterol ratio. Am. J. Cardiol. 72: 1215-1219.

9.- Bonithon-Kopp C., Scarabin P., Darne B., Malmejac A., Guize L. (1990) Menopause-related chenges il lipoproteins and some other cardiovascular risk factors. Int J Epidemiol; 19: 42-48.

10.- Vermeulen A. (1990) Plasma lipid and lipoprotein levels in obese post-menopausal womenn: effects of a short term low-protein diet and exercise. Maturitas; 12: 121-126.

11.- Sitruk-Ware R., de Palacios I (1989) Oestrogen replacement tjerapy and cardiovascular disease in post-menopausal womwn. A review. Maturitas 11: 259-274.

12.- Committe of Principal Investigators (1980) WHO cooperative trial on primary prevention of ischaemie heart disease using clofibrate to lower seruim cholesterol. Lancet II: 379-385.

13.- Lipid Research Clinics Program (1984) The Lipid Research Clinics Program: The lipid Research Clinics primary preventio trial results I and H. JAMA 251: 351-374

14.- Canner PL., Berge KG., Wenger NK. Et al (1986) Fifteen year mortality in coronary drug project patients: long term benefit with niacin. J. Am. Coll. Cardiol. 8: 1245-1255.

15.- Friek MH., Elo o:, Haapa K., et al (1987) Helsinki Heart Study: primary preventio trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 317: 1237-1245.

16.- Molgaard J., von Schenk H., Olsson AG (1988) Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolemia. Eur. Heart J 9: 541-555.

17.- Scglucter W., Keilani T., Batlle DC (1993) Metabolic effects of converting enzyme inhibitors: Focus on the reduction of cholesterol and lipoprotein (a) by fosinopril. Am. J. Cardiol. 72: 3711-4411.

18.- Gonzales GF., Chlimper D., Góñez C., Takara M. (1994) Estudios de los efectos de la caigua deshidratada (Cycladin) sobre el perfil lipidico de adultos de mediana edad de Lima. Diagnóstico (envíado a publicación e impreso por Laboratorios Farmindustria ?Lima).pp 1-8

19.- Friedewald WT., Levy RI., Fredickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin. Chem. 18: 499-502.

20.- ILIB (comité Peruano) (1994) Recomendaciones de ILIB para el diagnóstico de las dislipidemias en Latinoamérica. Lipid Digest 1: 1-20.

21.- Gambrell RD (1994) Management of hormone replacement therapy side effects. Menopause 1: 67-72.

22.- Gambrell RD., Terán A-Z (1991) Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am, J. Obst. Gynecol 165: 307.

23.- Hall V., Petitti DB., Ettinger B., Quesenberry C (1994) Does estrogen replacement therapy prevent height loss? Menopause 1: 3-9.

24.- Gharavi AG., Diamond JA., Smith DA., Phillips RA (1994) Niacin-induced myopathy. Am J Cardiol. 74: 841-842.

25.- Krauss RM (1994) Effects of hormone replacement therapy on plasma lipids and lipoproteins. Menopausal medicine. 2: 9-12.

26.- Grodsten P., Stamfer MJ (1994) Estrogen replacement therapy and cardiovascular disease. Menopausal Medicine 2: 1-4.